Lymphoma

Follow-up funding for two Collaborative Research Centres at the University of Cologne

Inherited long telomeres may drive broad risk for lymphoid cancers

ASCO 2026 Tip Sheet - Sylvester Comprehensive Cancer Center

Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.

UT MD Anderson shares latest research breakthroughs

Researchers at UT MD Anderson Cancer Center have made significant advancements in targeted therapy treatments for advanced lung cancer and early-stage classical Hodgkin lymphoma. The studies showcase high response rates with novel combination therapies and a new understanding of how an enzyme affects infertility and cancer progression.

Targeted maternal screening could prevent rare, deadly leukemia in the US

A new study found that targeted maternal screening can prevent adult T-cell leukemia/lymphoma, a rare and aggressive cancer caused by human T-cell leukemia virus type 1. The research identified high disease rates among non-Hispanic Caribbean-born US residents, particularly in Florida and New York.

Discovery of a novel vulnerability in aggressive lymphoma could change future therapy

A research team at the University of Cologne discovered that the protein cFLIP can be used to override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. Targeting cFLIP could re-activate cell death in lymphoma cells and provide a new therapy option.

Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics

Hodgkin lymphoma cells are immune cells stuck in an 'identity crisis,' unable to mature into functional plasma cells. The team discovered that these cells downregulate key B cell features and upregulate proteins to make them more like plasma cells, but not completely functioning as such.

Scientists identify a “protective switch” in the most common blood cancer, opening new doors for diagnosis and treatment

Researchers discovered that HDAC7 plays a dual role in immune system development and cancer progression. Restoring HDAC7 in cancer cells can slow or stop tumor growth, offering new hope for diagnosis and treatment.

Germ layer specification and organotropism in lymphoma invasion

This study reveals that lymphoma cells exhibit organotropism based on their germ-layer origin, with different mutations affecting migration patterns and survival. The research provides insights into the molecular basis of tumor invasion and metastasis, offering a new perspective for personalized cancer treatment.

Markers of lymphoma cancer relapse identified

A new study from the University of Missouri identified over 10 genetic or molecular markers that predict follicular lymphoma relapse early, allowing for targeted surveillance testing. This could improve patient outcomes, reduce unnecessary imaging tests, and lower healthcare costs.

Integration of single-cell multiomics data allows a more precise identification of rare cell types and states

Researchers developed an interpretable machine learning algorithm, scOMM, to classify cell types consistently across different single-cell methods. The integration strategies and scOMM establish a robust approach for cell atlas generation in complex tissues, leading to the discovery of previously undetected rare cell types.

The Josep Carreras Institute and the Chinese Institute of Hematology and Blood Diseases Hospital join forces to advance research in blood cancers

The Josep Carreras Leukaemia Research Institute is joining forces with the Chinese Institute of Hematology and Blood Diseases Hospital to advance blood cancer research. The partnership aims to develop joint translational research programmes and accelerate the development of curative therapies for patients with blood cancers.

Chaos in lymph nodes promotes cancer

Researchers find that rare stromal cells are responsible for maintaining immune cell organization in healthy lymph nodes. However, in aggressive lymphomas, this process breaks down due to a self-reinforcing inflammatory cycle, leading to tissue collapse and poorer outcomes.

Agent Orange linked to aggressive bone marrow cancer in Vietnam veterans

A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.

Alliance trial aims to improve outcomes for chronic lymphocytic leukemia

The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.

Twenty years cancer-free: one man’s story illustrates progress against follicular lymphoma

A new analysis shows that 42% of treated patients were functionally cured, marking a game-changer for an incurable disease. Recurrence rates declined drastically over time, from 6.8% in the first five years to 0.6% between 15 and 20 years.

UH researcher joins $3.2 million effort to develop promising new breast cancer treatment

Researchers are developing a new compound that can break down MDM2, a cancer-driving protein often found in triple-negative breast cancer, showing promise in shrinking tumors. The goal is to create an entirely new class of therapies for this aggressive and difficult-to-treat form of the disease.

Sylvester Cancer Tip Sheet for Feb. 2026

Researchers at Sylvester Cancer Institute have identified a potential workaround for chemotherapy resistance by blocking a key protein. The study aims to teach lymphoma patients practical tools to manage stress and improve their daily quality of life through the SMART 3RP Lymphoma study. Meanwhile, the institute is expanding cancer dis...

Case report explores potential link between mRNA COVID-19 vaccines and cancer

A case report investigates a woman's development of acute lymphoblastic leukemia and lymphoblastic lymphoma after receiving her second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine, highlighting potential genetic and molecular mechanisms involved in disease pathogenesis.

Dana-Farber research helps drive FDA label update for primary CNS lymphoma

CAR T-cell therapy is now available for eligible primary CNS lymphoma patients, thanks to Dana-Farber-led research. The FDA label update removes a prior exclusion and may expand treatment options for relapsed or refractory patients.

How a heart medication could unlock a new targeted approach in lymphoma

A team of researchers at VCU Massey Comprehensive Cancer Center has discovered an innovative way to use a drug already approved in treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, effectively killing cancer cells and reducing tumor growth with little to no toxicity. The study found that RBF4...

The ACHILLES project will train a new generation of researchers in experimental haemato-oncology to tackle leukemia and lymphoma

The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.

MD Anderson shares latest research breakthroughs

The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...

Evaluation of cancer reports following COVID-19 vaccination and infection

A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.

Promising innovative combination therapy for Burkitt's lymphoma

Researchers at Kanazawa University have developed a new combination therapy that combines CAR-T cell therapy with a SUMOylation inhibitor, which effectively suppresses MYC activity and slows the growth of Burkitt's lymphoma cells. The approach extends survival rates in mouse models by up to 80%.

B cells transiently unlock their plasticity, risking lymphoma development

A new study reveals that mature B cells temporarily gain plasticity during the antibody-making process, which could explain how many lymphomas develop from mature B cells. Researchers discovered that this epigenetic change is tightly regulated and can be hijacked by specific mutations to promote lymphomagenesis.

Sylvester Cancer Tip Sheet for December 2025

A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.

Early relapse predicts poor outcomes in aggressive blood cancer

A global study found that patients with mature nodal T-cell lymphoma who relapsed within 12 months of initial treatment had worse survival outcomes, but improved survival when treated with targeted therapies instead of chemotherapy. The results suggest the need for personalized treatment strategies for high-risk patients.

USC researchers develop next-generation CAR T cells that show stronger, safer response in animal models

Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.

Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

A new trial shows pirtobrutinib to be more effective than bendamustine plus rituximab in treating previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The drug demonstrated improved survival rates, a favorable safety profile, and lower adverse event rates compared to the standard treatment.

ASH 2025: Milder chemo works for rare, aggressive lymphoma

A new study finds that most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than intensive chemotherapy. The R-CHOP regimen has shown strong four-year survival rates for THRLBCL patients without significant side effects.

From novel therapies to first-in-human trials, City of Hope advances blood cancer care at the American Society of Hematology (ASH) annual conference

Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.

A routine blood test could help predict who benefits most from CAR T-cell therapy

A study found that measuring a patient's absolute lymphocyte count can predict their response to CAR T-cell therapy for non-Hodgkin lymphoma. Patients with higher lymphocyte counts and faster increases tend to have better outcomes, including progression-free survival and overall survival.

ASH 2025: New combination approach aims to make CAR T more durable in lymphoma

A new clinical trial suggests that combining bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may significantly enhance one-year progression-free survival for people with aggressive lymphoma. The study found that 90% of patients were in complete remission at day 90, and about 80% remained in remission at one y...

Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

A new study shows that adding epcoritamab to standard second-line therapy significantly improves follicular lymphoma outcomes, including a nearly 80% reduction in risk of death or disease progression. The treatment was also found to be effective for patients who received it on an outpatient basis.

ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma

The TRANSCEND FL trial demonstrates the effectiveness of lisocabtagene maraleucel in achieving durable remissions and favorable safety profiles in patients with relapsed or refractory follicular lymphoma. The therapy produced a 97% overall response rate, with most patients remaining in remission after three years.

ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment

A new study presented at ASH 2025 suggests that a virtual program focusing on diet and exercise can help reduce the severity of side effects associated with lymphoma treatment. The program, LIFE-L, showed significant improvements in symptoms such as anxiety, depression, pain, fatigue, and constipation among participants.

ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma

A new study by University of Texas M.D. Anderson Cancer Center researchers identified CD40 overexpression as a potential biomarker associated with improved overall survival in angioimmunoblastic T cell lymphoma (AITL). This discovery could lead to therapeutic strategies to improve outcomes for this challenging disease.

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

A new study presented at the 2025 American Society of Hematology meeting revealed that subtle disruptions in genome architecture can predispose individuals to lymphoma. The research found that damaged 3D genome architecture can silence key tumor suppressor genes, creating fertile ground for malignancy.

The Josep Carreras Institute leads a global alliance to eradicate Follicular Lymphoma

Follicular lymphoma is a complex cancer with an unpredictable clinical course, prompting the need for innovative diagnostic tools and treatment strategies. An international alliance, ERADICATE, aims to address this challenge through AI-powered analysis, genomics, and immunology research.

ASH 2025 posters preview from Sylvester Comprehensive Cancer Center

Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.

Lymphoma and targeted therapy: resistance mechanisms and future solutions

Lymphomas develop resistance to targeted therapies through various mechanisms, including loss of target antigens, reactivation of growth pathways, and changes in tumor microenvironment. Researchers explore new treatment approaches, such as dual-target therapies and biomarker-guided therapy, to overcome these challenges.

Chinese Neurosurgical Journal study decodes clinical features of tumor in brain ventricles

Researchers analyzed 29 new and 22 previously reported cases of PCNSL involving the ventricles, finding different clinical symptoms such as headache, dizziness, and vision impairment. The study suggests that despite its unusual location, ventricular PCNSL behaves like other forms of brain lymphoma, with a recommended treatment strategy...

City of Hope to present breakthroughs in blood cancer, microbiome research and cellular therapies at ASH 2025

City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.

Breakthrough gives hope in fight against aggressive form of blood cancer

Researchers discovered a new subtype of DLBCL, 'Mann-type DLBCL', which is characterized by the presence of a specific sugar called mannose. This sugar promotes the survival and growth of cancer cells, making them resistant to conventional treatments.

ASH 2025 tip sheet: Sylvester researchers contribute to more than 35 oral presentations at ASH Annual Meeting

Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.

MSK Research Highlights, October 31, 2025

A new study from Memorial Sloan Kettering Cancer Center identifies unique genetic signatures in cancer patients of non-European ancestry and finds adding immunotherapy can boost effectiveness for hard-to-treat follicular lymphomas. Additionally, researchers discover a web-based system to report head-and-neck cancer concerns, leading to...

MD Anderson shares latest research breakthroughs

Researchers at MD Anderson Cancer Center identified distinct cellular microenvironments in diffuse large B-cell lymphoma tumors, providing a framework to develop therapies that engage the patient's immune system. Additionally, a study found widespread misbeliefs about the cancer risks of alcohol among Americans, highlighting the need f...

Rare case of pancreatic Hodgkin lymphoma highlights importance of early diagnosis

A rare case of pancreatic Hodgkin lymphoma was reported, emphasizing the need for tissue diagnosis before definitive treatment. The patient's symptoms and imaging findings initially raised concern for pancreatic adenocarcinoma, but a biopsy revealed nodular sclerosis subtype of Hodgkin lymphoma.

Spatial analysis finds immune-rich pockets in diffuse large B-cell lymphoma tumors with clear treatment potential

A study by University of Texas MD Anderson Cancer Center researchers has identified seven distinct cellular microenvironments in diffuse large B-cell lymphoma (DLBCL) tumors. These microenvironments showed different mixes of cells and patterns of communication between tumor B-cells and immune cells.

Sylvester Cancer Tip Sheet for October 2025

Recent studies from Sylvester have uncovered links between breast cancer, Superfund sites and social adversity. Researchers are also exploring the use of artificial intelligence (AI) in interpreting mammograms more accurately.

The Josep Carreras Institute, at the forefront of spatial biology

The Josep Carreras Institute is pioneering Spatial Transcriptomics to understand tumor structure at the cellular level. The institute's guidance on this methodology offers practical solutions for improving reproducibility and clinical application.

New combination therapy shows promise for aggressive lymphoma resistant to immunotherapy

A new combination therapy combining epigenetic therapy with anti-PD-1 antibody showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma. The treatment triggered viral mimicry, restoring immune sensitivity and improving survival rates.

Can digital health tools help younger cancer survivors better predict future health risks?

A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.

Study assesses cancers in children exposed to medical imaging

A study published in The New England Journal of Medicine found that nearly 4 million children and adolescents were at higher risk of developing blood cancers due to radiation exposure from medical imaging. The researchers estimated that up to 10% of pediatric blood and bone marrow cancers may be attributable to radiation exposure.

Damon Runyon Cancer Research Foundation awards $4.8 million to exceptional early-career scientists

The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.

Novel study reveals three new follicular lymphoma subtypes guides precision treatment

Researchers identified three distinct molecular subtypes of follicular lymphoma, offering insights into personalized treatment plans. The subtypes C1, C2, and C3 differ in their genetic profiles and tumor microenvironments, guiding the use of specific therapies.

Study explains how lymphoma rewires human genome

A study reveals that translocations in mantle cell lymphoma boost the activity of 50 genes on a single chromosome, expanding potential drug targets. The discovery also identifies new cancer driver genes and offers insights into early detection strategies.

New research program to tackle childhood leukemia at the Josep Carreras Institute

The Josep Carreras Leukaemia Research Institute is launching a joint research programme on childhood leukaemia, aiming to develop common strategies and improve treatments for the disease. Paediatric leukaemia remains a significant challenge due to its low incidence and high mortality rate.

Major progress in fertility preservation after treatment for cancer of the lymphatic system

An international study has shown that BrECADD preserves fertility significantly better than eBEACOPP without worsening recovery chances. After treatment, 95% of women and 86% of men had normal hormone levels, enabling more pregnancies and births.